International Public Partnerships buys Frankfurt cop shop – International Public Partnerships Limited has entered into a binding commitment to acquire a stake in the new public private partnership police centre of South-East Hesse in Offenbach. International Public Partnerships has committed to invest c.EUR8 million for a 45% shareholding in the project. The project has been […]
Edinburgh Worldwide gets new deputy managers – Following discussion between the board and managers, Edinburgh Worldwide has announced the appointment of Svetlana Viteva and Luke Ward as deputy portfolio managers with immediate effect. Svetlana and Luke are part of Baillie Gifford’s Global Discovery investment team which is headed by Douglas Brodie, the manager of Edinburgh Worldwide. This […]
Isaly steps down from OrbiMed and Worldwide Healthcare Trust Veteran US biotech analyst and OrbiMed Capital founder Samuel Isaly has stepped down from his role as Managing Partner and separately as a director of UK-listed Worldwide Healthcare Trust WWH, which is managed by OrbiMed alongside Biotech Growth Trust BIOG. Isaly will be replaced at the New […]
Gilead acquires Cell Design Labs to bolster CAR-T presence Leading US biotech Gilead Sciences is to acquire privately-held Cell Design Labs in a structured buy out valued at to $567m, including the 12.2% shareholding it already holds as a result of its $12bn acquisition of Kite Pharmaceuticals earlier this year. The Kite deal propelled Gilead […]
Alexion stock rises on reports of activist investor – Stock in the US rare disease specialist Alexion Pharmaceuticals is up 6% this morning on reports that the famed New York-based activist hedge fund Elliot Management has taken a stake. Elliott has reportedly threatened to initiate a proxy battle potentially to replace the relatively new management team […]
FDA OK for Alexion’s Soliris in myasthenia gravis US approval for Alexion’s complement inhibitor Soliris in anti-acetylcholine receptor antibody-positive generalised myasthenia gravis could double the market for a product that is already selling $3bn/year, if some of the most optimistic sell-siders are to be believed. Soliris, which is famously one of, if not the, most […]
Electra underperforms as it shrinks – Electra Private Equity reports that, for the year ended 30 September 2017, its NAV total return was 9%, well behind that of the Mid 250 Index at 14%. Including their third special dividend announced 23 October 2017, they have returned GBP1.8bn to shareholders since 1 October 2016. The shareholder return was […]
Baring Emerging Europe outperforms as Polish stocks soar – For the year ended 30 September 2017, Baring Emerging Europe returned 26.9% in NAV terms and 27.6% in share price terms against a 21.4% return for its benchmark, the MSCI Emerging Markets Europe 10/40 Index. The dividend has been increased from 23p to 32p. The manager […]
Henderson European Focus manager loves Carlsberg – Henderson European Focus Trust has published results covering the year ended 30 September 2017. Performance highlights The ordinary share price(1) total return (including dividends reinvested) was 35.9% (2016: 8.6%). The net asset value total return was 21.7% compared to a total return from the benchmark (World Europe ex […]
Shaftesbury looks to raise £265m as buys in Broadwick Street – Shaftesbury is placing up to 27,855,508 ordinary shares at 265p per share to raise gross proceeds of £265m. 952p is the same level as the EPRA NAV at the end of September 2017 and it is a 4% discount to the share price on […]
